Suzanne Shusterman, MD
Attending Physician, Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Assistant Professor of Pediatrics, Harvard Medical School
Image
Suzanne Shusterman, MD
Attending Physician, Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Assistant Professor of Pediatrics, Harvard Medical School
Medical Services
Languages
English
Education
Internship
Pediatrics
Boston Children's Hospital
1994
Boston
MA
Medical School
University of Massachusetts
1993
Worcester
MA
Residency
Pediatrics
Boston Combined Residency Program (BCRP)
1996
Boston
MA
Undergraduate School
University of Pennsylvania
1989
Philadelphia
PA
Fellowship
Pediatric Hematology -Oncology
Children's Hospital of Philadelphia
2000
Philadelphia
PA
Certifications
American Board of Pediatrics (Hematology-Oncology)
Publications
Hypofractionated Palliative Radiotherapy for Relapsed and Refractory High-Risk Neuroblastoma. View Abstract
A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma. View Abstract
Author Correction: Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer. View Abstract
Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer. View Abstract
Patterns of recurrence after radiotherapy for high-risk neuroblastoma: Implications for radiation dose and field. View Abstract
Factors influencing parents' choice of palliative treatment goals for children with relapsed or refractory neuroblastoma: A multi-site longitudinal survey study. View Abstract
STK11 Adnexal Tumor in an Adolescent Female: Diagnostic Pitfalls of a Recently Described Entity. View Abstract
A single-institution pediatric and young adult interventional oncology collaborative: Novel therapeutic options for relapsed/refractory solid tumors. View Abstract
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results. View Abstract
Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor. View Abstract
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). View Abstract
Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease. View Abstract
Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors. View Abstract
Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. View Abstract
Facial Paralysis From Post-transplant Lymphoproliferative Disorder. View Abstract
Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology. View Abstract
The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor. View Abstract
Racial and Ethnic Differences in Communication and Care for Children With Advanced Cancer. View Abstract
A Novel ALK Fusion in Pediatric Medullary Thyroid Carcinoma. View Abstract
Unrealistic parental expectations for cure in poor-prognosis childhood cancer. View Abstract
Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study. View Abstract
Evaluation of the utility of 99m Tc-MDP bone scintigraphy versus MIBG scintigraphy and cross-sectional imaging for staging patients with neuroblastoma. View Abstract
Patterns of Relapse in High-Risk Neuroblastoma Patients Treated With and Without Total Body Irradiation. View Abstract
Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. View Abstract
A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma. View Abstract
Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors. View Abstract
Neuroblastoma presenting as facial nerve palsy and bulging tympanic membrane. View Abstract
Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621). View Abstract
Radiation exposure to family caregivers and nurses of pediatric neuroblastoma patients receiving 131I-metaiodobenzylguanidine (131I-MIBG) therapy. View Abstract
Adoptive transfer of autologous T cells improves T-cell repertoire diversity and long-term B-cell function in pediatric patients with neuroblastoma. View Abstract
Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study. View Abstract
Iodine-131-labeled meta-iodobenzylguanidine therapy of children with neuroblastoma: program planning and initial experience. View Abstract
Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study. View Abstract
Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study. View Abstract
Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium. View Abstract
Genotypes of NK cell KIR receptors, their ligands, and Fc? receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. View Abstract
Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. View Abstract
Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study. View Abstract
Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. View Abstract
Neuroblastoma View Abstract
Expression profiling identifies BAI2, an endogenous inhibitor of angiogenesis, as a traget for somatic inactivation in high-risk neuroblastoma View Abstract
131I-Metaiodobenzylguanidine(131I-MIBG) double infusion with autologous stem cell transplant (ASCT) for neuroblastoma: A New Approaches to Neuroblastoma Therapy (NANT) study View Abstract
Prospects for therapeutic inhibition of neuroblastoma angiogenesis. View Abstract
Methionine aminopeptidase 2 inhibition is an effective treatment strategy for neuroblastoma in preclinical models. View Abstract
Somatic Inactivation of brain-specific angiogenesis inhibitor-2 (BAI2) during the malignant evolution of high-risk neuroblastoma View Abstract
131I-MIBG double infusiton with autologous stem cell transplant (ASCT) for neuroblastoma - a New Approaches to Neuroblastoma Therapy (NANT) study View Abstract
Genome-wide transcriptome analysis for neuroblastoma gene discovery and refinement of clinical risk group prediction View Abstract
Detection of single-copy chromosome 17q gain in human neuroblastomas using real-time quantitative polymerase chain reaction. View Abstract
Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2. View Abstract
ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas. View Abstract
Functional genomic analysis of neuroblastoma for high resolution mapping of 11q deletions View Abstract
Neuroblastoma View Abstract
Increased incidence of TP53 mutations in post-treatment neuroblastomas View Abstract
Transfusion of the patient with congenitally aquired coagulation defects View Abstract
Discovery of antiangiogenic targets induced by chemotherapy in a murine model of human neuroblastoma View Abstract
A reversible methionine aminopeptidase inhibitor potently inhibits growth of human neuroblastoma in xenotransplantation models View Abstract
Transplantation in Hematology and Oncology II View Abstract
Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13. View Abstract
Chromosome 11q23.3-q24.1 deletions in neuroblastoma (NB) View Abstract
ID2 is a MYCN target gene, but expression is not correlated with MYCN gene amplification in human neuroblastomas View Abstract
Angiogenesis inhibition is an effective adjuvant therapeutic strategy in neuroblastoma (NB) preclinical models View Abstract
A combined functional and expression profiling strategy for isolating neuroblastoma suppresso genes on chromosome 11 View Abstract
Prospective validation of real-time quantitative PCR for detection of MYCN amplifcation inprimary neuroblastoma specimens View Abstract
A functional and expression profiling stratefy for isolating neuroblastoma (NB) supressor genes on chromosome 11 View Abstract
The angiogenesis inhibitor tnp-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease. View Abstract
Angiogenesis inhibitor TNP-470 during bone marrow transplant: safety in a preclinical model. View Abstract
The growth rate of human neuroblastoma xenografts is decreased through inhibition of multiple angiogenic signaling pathways with SU668 View Abstract
The angiogenesis inhibitor TNP-470 effectively inhibits human neuroblastoma xenograft growth especially in the setting of subclinical disease View Abstract
Inhibition of the VEGF, PDGF and bFGF signaling pathways with SU6668 decreases the growth rate of human neuroblastoma xenografts View Abstract
Localization of a hereditary neuroblastoma predisposition gene to 16p12-p13. View Abstract
Inhibition of tumor growth in a human neuroblastoma xenograft model with TNP-470. View Abstract
Long term survivors of childhood leukemia. View Abstract
Effects of TRK receptor expression on angiogenesis in neuroblastoma cells View Abstract
Detection of unbalanced 17q gain in human neuroblastomas by real-time quantitative PCR View Abstract
Use of real-time quantitative PCR to detect unbalanced 17q gain in neuroblastoma cell lines and primary tumors View Abstract
Microcytic Anemia. Iron Deficiency Anemia View Abstract
Inhibitors of angiogenesis in minimal residual disease: safety post-BMT and efficacy in a preclinical model View Abstract
Preclinical evaluation of antiangiogenic therapy with TNP-470 for human neuroblastoma View Abstract
TNP-470 inhibits the growth rate and tumorigenicity of human neuroblastoma xenografts View Abstract
A 2.5-month-old girl with hyperbilirubinemia, hypoglycemia, and blindness. View Abstract